---
id: clostridioides-difficile_073
category: organisms
tags: [clostridioides-difficile, C-diff, CDI, fidaxomicin, vancomycin, bezlotoxumab, fecal-microbiota-transplant]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Clostridioides difficile Infection (CDI)

**Q:** What are the current treatment guidelines (2024) for initial and recurrent C. difficile infection, including fidaxomicin, bezlotoxumab, and fecal microbiota transplant?

**A:**

**Microbiology:**
- **Gram-positive, spore-forming anaerobic bacillus**
- Formerly Clostridium difficile → renamed Clostridioides difficile (2016)
- **Toxin-mediated disease:** Toxin A (enterotoxin), Toxin B (cytotoxin)
- **Hypervirulent strain:** NAP1/BI/027 (produces more toxin, associated with severe disease)

**Epidemiology:**
- **500,000 infections/year in US** (~30,000 deaths)
- Most common healthcare-associated infection
- Increasing community-acquired CDI

---

**Risk Factors:**

**Antibiotic Exposure (#1 Risk):**
- **Highest risk:** Fluoroquinolones, clindamycin, cephalosporins (especially 3rd generation), carbapenems
- **Lower risk:** Penicillins, macrolides
- **Risk persists** up to 3 months post-antibiotic

**Other Risk Factors:**
- Age ≥65 years
- Hospitalization/long-term care
- Proton pump inhibitors (controversial)
- Immunosuppression
- Inflammatory bowel disease
- Prior CDI

---

**Clinical Presentation:**

**Spectrum:**
- Asymptomatic carrier (colonization)
- Mild-moderate diarrhea
- **Severe/fulminant colitis** (toxic megacolon, perforation, sepsis)

**Symptoms:**
- **Watery diarrhea** (≥3 unformed stools/24h)
- **Abdominal pain, cramping**
- **Fever** (in severe cases)
- **Leukocytosis** (WBC often >15,000, can be >50,000)

**Severe CDI Criteria:**
- WBC ≥15,000 OR
- Creatinine ≥1.5× baseline

**Fulminant CDI:**
- Hypotension, shock, ileus, megacolon, perforation

---

**Diagnosis:**

**Testing:**
- **Nucleic acid amplification test (NAAT):** Detects toxin genes (high sensitivity, but detects colonization too)
- **Glutamate dehydrogenase (GDH) + toxin EIA:** Two-step algorithm
- **Toxin EIA alone:** Low sensitivity (not recommended)

**Key Points:**
- **DO NOT test formed stools**
- **DO NOT test for cure** (can remain positive for weeks)
- Test only **symptomatic** patients (≥3 unformed stools/24h)

**Imaging:**
- CT abdomen/pelvis: **Colonic wall thickening**, pericolonic stranding, "accordion sign" (severe)

---

**Treatment:**

**2024 IDSA/SHEA Guidelines:**

---

**1. Initial Episode (Non-Severe):**

**First-Line (Preferred):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Fidaxomicin** (preferred) | 200 mg PO BID | 10 days |
| **Vancomycin** (alternative) | 125 mg PO QID | 10 days |

**Key Point:**
- **Fidaxomicin preferred over vancomycin** (lower recurrence rate: 15% vs 25%)
- **Barrier:** Cost (~$3,500 vs ~$50 for vancomycin), insurance coverage challenges
- **Metronidazole:** NO longer recommended (high failure rates)

---

**2. Initial Episode (Severe):**

**Severe CDI Criteria:**
- WBC ≥15,000 OR
- Creatinine ≥1.5× baseline

**First-Line:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Fidaxomicin** (preferred) | 200 mg PO BID | 10 days |
| **Vancomycin** (alternative) | 125 mg PO QID | 10 days |

**Same as non-severe, but consider:**
- **Add bezlotoxumab** (see below) if high risk for recurrence

---

**3. Initial Episode (Fulminant):**

**Fulminant CDI:**
- Hypotension, shock, ileus, megacolon

**Treatment:**

| **Agent** | **Dosing** |
|-----------|------------|
| **Vancomycin** | 500 mg PO/NG QID |
| PLUS | |
| **Vancomycin enema** | 500 mg in 500 mL NS per rectum QID (if ileus) |
| PLUS | |
| **Metronidazole** | 500 mg IV q8h |

**Surgical Consultation:**
- **Indications:** Perforation, toxic megacolon, refractory shock, peritonitis
- **Procedure:** Subtotal colectomy with end ileostomy (high mortality 30-50%)
- **Alternative:** Diverting loop ileostomy + vancomycin lavage (emerging option)

---

**4. First Recurrence:**

**Definition:** CDI recurrence within 8 weeks of completing treatment

**Recurrence Rate:** 20-30% after first episode

**Treatment (Prolonged Course):**

| **Strategy** | **Regimen** |
|--------------|-------------|
| **Prolonged tapered/pulsed fidaxomicin** | 200 mg PO BID x 5 days, then 200 mg PO daily x 25 days |
| **Vancomycin taper** | 125 mg PO QID x 10-14d → BID x 7d → daily x 7d → every 2-3 days x 2-8 weeks |
| **Standard fidaxomicin** | 200 mg PO BID x 10 days |
| **Standard vancomycin** | 125 mg PO QID x 10 days (then CONSIDER taper) |

**Add Bezlotoxumab** (see below)

---

**5. Second or Subsequent Recurrence:**

**After ≥2 recurrences (≥3 total episodes):**

**Options (in order of preference):**

**A. Fecal Microbiota Transplant (FMT):**
- **FDA-approved products:**
  - **Rebyota** (fecal microbiota live-jslm): Single-dose rectal enema
  - **Vowst** (fecal microbiota spores live-brpk): Oral capsules x 3 days
- **Efficacy:** 80-90% cure rate
- **Timing:** After ≥2 recurrences (≥3 episodes total)

**B. Prolonged Tapered/Pulsed Fidaxomicin:**
- 200 mg PO BID x 5 days, then 200 mg PO daily x 25 days

**C. Vancomycin Taper:**
- See above regimen

**D. Bezlotoxumab Alone:**
- If FMT not available/declined

---

**Bezlotoxumab (Monoclonal Antibody Against Toxin B):**

**Indications:**
- **Add to antibiotics** for patients with:
  - **Prior CDI recurrence within 6 months** (strongest indication)
  - **First CDI + ≥1 risk factor for recurrence:**
    - Age ≥65 years
    - Immunocompromise
    - Severe CDI

**Dosing:**
- **10 mg/kg IV x 1** (single infusion during antibiotic course)

**Efficacy:**
- **Reduces recurrence by ~40%** (from 25-30% → 15-18%)
- **NNT = 8** to prevent 1 recurrence

**Key Point:**
- Does NOT treat active CDI (must use with antibiotics)
- Prevents recurrence by neutralizing toxin B

---

**6. Special Considerations:**

**Antibiotic Stewardship:**
- **STOP non-CDI antibiotics** if possible (↑ recurrence risk if continued)

**Probiotics:**
- **NOT recommended** during CDI treatment
- Controversial for prevention

**Proton Pump Inhibitors:**
- Consider stopping (controversial - weak association with CDI)

---

**Preventing Recurrence:**

**Risk Factors for Recurrence:**
- **Prior CDI recurrence** (#1 risk - up to 65% recurrence after 2nd episode)
- Age ≥65 years
- Immunosuppression
- Ongoing antibiotics
- Severe initial episode

**Strategies:**
- **Fidaxomicin over vancomycin** (15% vs 25% recurrence)
- **Bezlotoxumab** for high-risk patients
- **FMT** after ≥2 recurrences
- **Stop non-CDI antibiotics** when possible

---

**Infection Control:**

**Contact Precautions:**
- Private room
- Gown and gloves
- Hand hygiene: **Soap and water** (alcohol does NOT kill spores)

**Environmental Cleaning:**
- **Bleach-based disinfectants** (10% bleach solution OR EPA-approved sporicidal)
- UV-C disinfection devices

---

**Comparison: Treatment Options**

| **Agent** | **Initial Episode** | **Recurrence** | **Pros** | **Cons** |
|-----------|---------------------|----------------|----------|----------|
| **Fidaxomicin** | ✅ Preferred | ✅ Preferred | Lower recurrence (15%) | Expensive ($3,500) |
| **Vancomycin** | ✅ Alternative | ✅ Taper/pulse | Inexpensive ($50) | Higher recurrence (25%) |
| **Metronidazole** | ❌ Not recommended | ❌ Not recommended | N/A | High failure rates |
| **Bezlotoxumab** | Add for high-risk | ✅ Add | ↓ Recurrence by 40% | Expensive, IV only |
| **FMT** | ❌ No | ✅ After ≥2 recurrences | 80-90% cure | Invasive, FDA products limited |

---

**Mnemonic: "FVB for CDI"**
- **F**idaxomicin preferred (lower recurrence)
- **V**ancomycin alternative (inexpensive)
- **B**ezlotoxumab add for high-risk (prior recurrence, age ≥65, severe)

**Mnemonic: "FMT after 3 episodes"**
- **F**ecal microbiota transplant
- **M**ultiple recurrences (≥2 recurrences = 3 total episodes)
- **T**ransplant (Rebyota, Vowst)

**Clinical Pearls:**
- **Fidaxomicin preferred over vancomycin** (2024 guidelines) - lower recurrence (15% vs 25%)
- **Metronidazole NO longer recommended** (high failure rates)
- **Bezlotoxumab** (anti-toxin B antibody) reduces recurrence by 40% (NNT=8)
- **FMT after ≥2 recurrences** (≥3 total episodes) - 80-90% cure rate
- **FDA-approved FMT products:** Rebyota (rectal), Vowst (oral)
- **Vancomycin dose:** 125 mg QID (higher doses NO better)
- **Fulminant CDI:** Vancomycin PO + rectal + metronidazole IV + surgical consult
- **DO NOT test for cure** (remains positive for weeks)
- **Soap and water** for hand hygiene (alcohol does NOT kill spores)
- **Stop non-CDI antibiotics** if possible (↑ recurrence risk)
- **83% of clinicians use vancomycin** despite fidaxomicin preference (insurance coverage barriers)

**Media:** None

**Sources:** [IDSA/SHEA 2021 guidelines (updated 2024)], [AGA 2024 - FMT clinical practice guideline], [PMC 2024 - Clinician management preferences EIN survey], [AJMC 2024 - Treatment guidelines], [Am J Med 2024 - Management review], [UCSF 2025 - CDI adult treatment guideline], [PMC 2022 - Management comparison IDSA/ESCMID/ASID], [AAFP 2022 - IDSA focused update]
